{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-135768","form_type":"8-K","ticker":"BOLD","cik":"0001782303","company_name":"Boundless Bio, Inc.","filed_at":"2024-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.594183+00:00","generated_at":"2026-05-29T04:11:37.769558+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Boundless Bio stops BBI-825 trial, CMO and CBO depart; cash runway extends to 2027","bullets":["BBI-825 Phase 1/2 STARMAP trial discontinued due to lack of dose-proportional PK, increased development costs, and competitive landscape changes.","BBI-355 Phase 1/2 POTENTIATE trial on track for initial clinical data readout in H2 2025; enrollment ongoing.","Third ecDTx program targeting a kinesin for ecDNA segregation; development candidate nomination expected mid-2025, IND in H1 2026.","CMO Klaus Wagner and CBO Neil Abdollahian departing; James Freddo named Interim CMO while search for permanent CMO begins.","Cash, equivalents, and short-term investments sufficient to fund operations into 2027 through anticipated milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-135768","json":"https://secwatch.observer/filing/0000950170-24-135768.json","markdown":"https://secwatch.observer/filing/0000950170-24-135768.md","text":"https://secwatch.observer/filing/0000950170-24-135768.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782303/000095017024135768/0000950170-24-135768-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782303/000095017024135768/bold-20241206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T04:11:37.769558+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}